..... yet ONTY has recently come to my attention (long story - no pun intended). In my preliminary research, it looks like the balance sheet is improving, but the efficacy of L-BLP25 was overall a disappointment to many.
I have no position here. What I'm wondering is if the lung cancer vaccine turns out not to be profitable, what else has this company got to make it an interesting place to invest money. Thanks!